

IFW

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 19, 2004.

  
Kurt A. Summe, Reg. No. 36,023

7/19/04

Date



PATENT  
ATTY. DOCKET NO: XANO-42/119

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Heasley Art Unit: 1614  
Serial No. 10/774,803 Examiner: Unknown  
Filed: February 9, 2004  
Title: A STABLE PARENTERAL FORMULATION OF LEVOMEPROMAZINE  
AND A METHOD FOR STABILIZING SAID FORMULATION

Cincinnati, Ohio

July 19, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are enclosed. No representation is made that the cited art is the only art or that the cited art represents the best art. The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe that any fees are due in connection with this submission as there has yet to be a first Action in this case. However, if such petition is due or any

fees are necessary, the Commissioner may consider this to be a request for such and charge any necessary fees to Deposit Account 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.



Kurt A. Summe  
Reg. No. 36,023

2700 Carew Tower  
Cincinnati OH 45202  
(513) 241-2324 Voice  
(513) 421-7269 Facsimile

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42	SERIAL NO. 10/774,803
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Ralph A. Heasley	
				FILING DATE February 9, 2004	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OIP E	A.A						
JUL 22 2004 PATENT & TRADEMARKS	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A.R	Dahl, Svein G., <u>Pharmacokinetics of methotriptazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442
A.S	Dahl, Svein, G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40
A.T	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotriptazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42	SERIAL NO. 10/774,803
O I P E JUL 22 2004 S C B U S P T O P A T E N T & T R A D E M A R K O F F I C E		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Ralph A. Heasley	
		(Use several sheets if necessary) (37 CFR 1.98(b))		FILING DATE February 9, 2004	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
B.A						
B.B						
B.C						
B.D						
B.E						
B.F						
B.G						
B.H						
B.I						
B.J						
B.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, Mack Publishing Co., PA, pp.878-893
B.S	Gibson, Ed., <u>Pharmaceutical Preformulation and Formulation</u> , IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458
B.T	Hals, PA et al., <u>Metabolism of levomepromazine in man</u> , European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/42	SERIAL NO. 10/774,803
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Ralph A. Heasley	
				FILING DATE February 9, 2004	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.A.							
JUL 22 2004 PATENT & TRADEMARK OFFICE	C.B.						
	C.C.						
	C.D.						
	C.E.						
	C.F.						
	C.G.						
	C.H.						
	C.I.						
	C.J.						
	C.K.						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L.						
	C.M.						
	C.N.			/			
	C.O.						
	C.P.						
	C.Q.						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C.R.	Sztruhar, I et al., <u>Liquid chromatographic resolution of the enantiomers of psychotropic drug levomepromazine (methotriimeprazine) with beta-cyclodextrin-bonded chiral stationary phase</u> , Journal of Pharmaceutical & Biomedical Analyses, 1993; 3:263-266
C.S.	
C.T.	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.